Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to identify cellular and molecular determinants of response to neoadjuvant immunochemotherapy in women aged 18 or older with early-stage triple-negative breast cancer (TNBC). The main questions it aims to answer are: * Can detailed immune profiling of the tumor and its microenvironment predict pathological complete response (pCR, RCB-0) versus partial/non-response (RCB-I, II, III) to neoadjuvant immunochemotherapy? * Are there specific immune or molecular biomarkers (e.g., TILs, CD3/8/20, FoxP3, PDL1, transcriptomic signatures) associated with progression-free survival and overall survival in this population? Researchers will compare patients achieving pCR (RCB-0) to those with residual disease (RCB-I, II, III) to determine if immune and molecular profiles can discriminate responders from non-responders and guide personalized treatment strategies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18 lat lub więcej
- •Potwierdzony histologicznie rak piersi typu triple-negative, stadium II lub III
- •Kwalifikacja do leczenia przedoperacyjnego immunochemioterapią
- •Wymagane umieszczenie znacznika w guzie przed biopsją
- •Podpisana świadoma zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Kobieta w ciąży lub karmiąca piersią
- •Zaburzenia krzepnięcia krwi
- •Osoby pod opieką sądową lub pozbawione wolności
- •Brak ubezpieczenia społecznego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Centre Eugène Marquis
Rennes, France
Trial contact
Valérie JOLAINE
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.